Hardik Parikh
Stock Analyst at J.P. Morgan
(0.12)
# 4,719
Out of 5,058 analysts
31
Total ratings
20%
Success rate
-26.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Hardik Parikh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Upgraded: Hold | $23 → $37 | $36.35 | +0.41% | 13 | Oct 13, 2026 | |
| SYRE Spyre Therapeutics | Initiated Coverage: Buy | $110 | $85.90 | +28.06% | 1 | Oct 1, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $100 | $23.91 | +318.24% | 7 | Aug 17, 2026 | |
| KLRA Kailera Therapeutics | Reiterated: Buy | $30 | $11.33 | +164.78% | 2 | Aug 12, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $75 → $65 | $28.34 | +129.36% | 8 | Aug 11, 2026 |
Pacira BioSciences
Oct 13, 2026
Upgraded: Hold
Price Target: $23 → $37
Current: $36.35
Upside: +0.41%
Spyre Therapeutics
Oct 1, 2026
Initiated Coverage: Buy
Price Target: $110
Current: $85.90
Upside: +28.06%
Structure Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $100
Current: $23.91
Upside: +318.24%
Kailera Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $30
Current: $11.33
Upside: +164.78%
Viking Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $75 → $65
Current: $28.34
Upside: +129.36%